Patient One is a coalition of academia, development experts, a pharmaceutical company and social investors, collaborating closely with patient representatives and clinical experts to develop an accessibly priced treatment for cystinosis.
Produce a new formulation to improve cystinosis treatment options for patients.
Provide all cystinosis patients with accessible and high-standard pharmaceutical care.
We are a coalition of several parties who have contributed to the research and development of a novel therapy, by investing both time and money.
There are currently six shareholders who have invested time and or money in Patient One.
Tiofarma – Dutch pharmaceutical research and development company specialised in the development and distribution of small molecules
Nierstichting Nederland – Non-profit organisation with the mission to improve the quality of life of kidney patients
OUR CORE TEAM
Patient One is a collaboration of academia, development experts, a pharmaceutical company and social investors, which collaborates closely with patient representatives and clinical experts. The collaboration is led by the core team.
To make our next steps in the development process possible, we need additional investments.
Will you join our cause?